MD1 Microbial Prep Solution 30 ml
- Known as:
- MD1 Microbial Prep Solution 30 milliliter
- Catalog number:
- 40-3703-03
- Product Quantity:
- 30ml
- Category:
- -
- Supplier:
- Gene Link
- Gene target:
- MD1 Microbial Prep Solution 30
Related genes to: MD1 Microbial Prep Solution 30 ml
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: MD1 Microbial Prep Solution 30 ml
Related articles to: MD1 Microbial Prep Solution 30 ml
- - Source: PubMed
Publication date: 2026/04/16
Abubakar Abass TandoObeng Yaa AdutwumwaaMensa Winfred KofiAnyidoho Daniel SelaseAidoo-Frimpong Gloria - While emergency preparedness preparations are typically focused on the most commonly occurring events such as natural disasters, disease outbreaks, and small-scale human-made disasters, concern for disasters involving mass gatherings is growing, particularly with previously less common nuclear, radiological, and explosive incidents. An example is provided of potentially useful preparedness for these events with the upcoming FIFA World Cup 2026, expected to be one of the largest sporting events in USA history. Trainings and protocols are reviewed, with a specific suggestion of a scorecard for prioritizing preparedness. Particular focus is also given to integrated surge pathways in this response. By combining evidence-based risk communication, burn surge planning, and the scorecard approach to prioritize and coordinate actions across host cities, organizers can reduce preventable morbidity and mortality. - Source: PubMed
Publication date: 2026/04/16
Dallas Cham EFowler RayNoel ChaverlePandya JayRyan Benjamin JSchwartz DaganSwienton Raymond - - Source: PubMed
Publication date: 2026/04/16
Brackstone KenDenny JackHansen Alexandra ChristineTrautwein MicahBadri ElsaraCheran AparnaToal RobinTertyshnyi SerhiiAsgedom AkezaMokhallalati AhmedWild Hannah - The CAPRISA 018 Phase I trial evaluated the safety, tolerability and pharmacokinetics of a 110 mg tenofovir alafenamide (TAF) implant for HIV prevention in South African women. This follow-up cohort study, CAPRISA 097, assessed the long-term resolution of implant site reactions (ISRs) after implant removal and explored user acceptability and implant attribute preferences to inform the development of next-generation pre-exposure prophylaxis (PrEP) implants. - Source: PubMed
Gengiah Tanuja NLewis LaraHarkoo IshanaMyeni NqobileMansoor Leila EKarim Salim S AbdoolKarim Quarraisha Abdool - Previous research on the influence of substance use on PrEP uptake and adherence among transgender women has either relied on cross-sectional analyses or on combined samples of cisgender men who have sex with men and a much smaller subsample of transgender women. To the best of our knowledge, no longitudinal study has examined the relationship of substance use and PrEP use/adherence among young transgender women and nonbinary people assigned male at birth (TNBY). We sought to understand whether substance use (i.e., binge drinking, marijuana use, and illicit drug use) predicts PrEP uptake and adherence for TNBY over time. Using a sample of 242 young and racially/ethnically diverse TNBY from the RADAR cohort study, we performed bivariate and multivariate generalized estimating equations binary logistic regression to assess whether substance use predicted PrEP use and adherence and latent growth curve modeling to examine trends in self-reported PrEP use over time. There were no significant differences in PrEP use or adherence by race/ethnicity, gender or educational attainment. In multivariable models, binge drinking (OR 1.37, 95% CI 1.08-1.74), number of condomless sex partners (OR 1.08, 95% CI 1.04-1.13), and HIV/STI testing (OR 2.20, 95% CI 1.65-2.92) were all significantly positively associated with PrEP use in the past 6 months. Binge drinking (OR 1.27, 95% CI 0.97-1.67), number of condomless sex partners (OR 1.09, 95% CI 1.04-1.13), and HIV/STI testing (OR 1.85, 95% CI 1.35-2.53) were significantly positively associated with current PrEP use. Both age (OR 1.25, 95% CI 1.02-1.54) and binge drinking (OR 8.66, 95% CI 2.12-35.30) were significantly positively associated with PrEP adherence. Cannabis use was significantly negatively associated with PrEP adherence (OR 0.89, 95% CI 0.82-0.97). Latent growth curve modeling detailed that the proportion of participants using PrEP significantly increased over time across age, reducing initial differences in PrEP use by age. These findings provide valuable insights into the relationship between substance use and PrEP use and adherence, showing the different effects of binge drinking and problematic cannabis consumption on PrEP outcomes. These findings emphasize the importance of nuanced and intersectional approaches to HIV prevention, considering both demographic variability and behavioral health factors. - Source: PubMed
Publication date: 2026/04/15
Zamantakis AlithiaQueiroz Artur A F L N